A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis, N Engl J Med, vol.362, pp.416-442, 2010. ,
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial, Lancet Neurol, vol.13, issue.3, pp.257-67, 2014. ,
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine, Neurol Neuroimmunol Neuroinflamm, vol.2, issue.6, p.158, 2015. ,
Cancer risk in patients with multiple sclerosis: potential impact of disease-modifying drugs, CNS Drugs, vol.378, issue.2, pp.169-182, 2018. ,
Decreased prevalence of cancer in patients with multiple sclerosis: a casecontrol study, PLoS One, vol.12, issue.11, pp.188120-188131, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01650724
Cancer and multiple sclerosis in the era of disease-modifying treatments, J Neurol, vol.258, issue.7, pp.1304-1315, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00996630
A feedforward mechanosignaling loop confers resistance to therapies targeting the MAPK pathway in BRAFmutant melanoma, Cancer Res, vol.80, issue.10, pp.1927-1968, 2020. ,
URL : https://hal.archives-ouvertes.fr/inserm-02889519
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study, Mult Scler, vol.24, issue.12, pp.1594-604, 2018. ,
Safety of cladribine tablets in the treatment of patients with multiple sclerosis. An integrated analysis, Mult Scler Relat Dis, vol.29, pp.157-67, 2019. ,